Piperacillin

Revision as of 17:47, 2 June 2009 by Brian Blank (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Piperacillin
Clinical data
Pregnancy
category
  • B
Routes of
administration
IV, IM
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailabilitynot absorbed orally
Metabolismlargely not metabolised
Elimination half-life36–72 minutes
Excretion20% in bile, 80% unchanged in urine
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC23H26N5O7S
Molar mass516.548 g/mol

WikiDoc Resources for Piperacillin

Articles

Most recent articles on Piperacillin

Most cited articles on Piperacillin

Review articles on Piperacillin

Articles on Piperacillin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Piperacillin

Images of Piperacillin

Photos of Piperacillin

Podcasts & MP3s on Piperacillin

Videos on Piperacillin

Evidence Based Medicine

Cochrane Collaboration on Piperacillin

Bandolier on Piperacillin

TRIP on Piperacillin

Clinical Trials

Ongoing Trials on Piperacillin at Clinical Trials.gov

Trial results on Piperacillin

Clinical Trials on Piperacillin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Piperacillin

NICE Guidance on Piperacillin

NHS PRODIGY Guidance

FDA on Piperacillin

CDC on Piperacillin

Books

Books on Piperacillin

News

Piperacillin in the news

Be alerted to news on Piperacillin

News trends on Piperacillin

Commentary

Blogs on Piperacillin

Definitions

Definitions of Piperacillin

Patient Resources / Community

Patient resources on Piperacillin

Discussion groups on Piperacillin

Patient Handouts on Piperacillin

Directions to Hospitals Treating Piperacillin

Risk calculators and risk factors for Piperacillin

Healthcare Provider Resources

Symptoms of Piperacillin

Causes & Risk Factors for Piperacillin

Diagnostic studies for Piperacillin

Treatment of Piperacillin

Continuing Medical Education (CME)

CME Programs on Piperacillin

International

Piperacillin en Espanol

Piperacillin en Francais

Business

Piperacillin in the Marketplace

Patents on Piperacillin

Experimental / Informatics

List of terms related to Piperacillin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Piperacillin is an extended spectrum beta-lactam antibiotic of the ureidopenicillin class. It is normally used together with a beta-lactamase inhibitor such as tazobactam, which is commercially available as Tazocin or Zosyn. The combination has activity against many Gram-positive and Gram-negative pathogens and anaerobes, including Pseudomonas aeruginosa.

Piperacillin/tazobactam is administered intravenously. Its main uses are in intensive care medicine (pneumonia, peritonitis), some diabetes-related foot infections and empirical therapy in febrile neutropenia (e.g. after chemotherapy).

Dosing

Piperacillin is not absorbed orally, and must therefore be given by intravenous or intramuscular injection. The doses available differ slightly from country to country.

The doses listed here are adult doses. In the U.S., the dose is 3.375–4.5 g every 6 hours. In the UK, the usual dose is 4.5 g every 8 hours; but is licensed to be given as 2.25–4.5 g every 6–8 hours. The drug may also be given by continuous infusion, but this has not been shown to be superior.[1]

Trade names and preparations

Piperacillin alone:

  • Pipracil (U.S. only)

Piperacillin/tazobactam:

  • Tazocin (UK, marketed by Lederle)
  • Tazocin (Japan, marketed by Toyama)
  • Tazocin (New Zealand, marketed by Wyeth)
  • Zosyn (U.S., marketed by Wyeth-Ayerst)

References

  1. Lau W, Mercer D, Itani K; et al. (2006). "Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection". Antimicrob Agents Chemother. 50 (11): 3556&ndash, 61. PMID 16940077.

External links



Template:SIB Template:WH Template:WS